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Abstract
Background—Skin cancer, the most common cancer in the U.S., is a major public health 
problem. The incidence of nonmelanoma and melanoma skin cancer is increasing; however, little 
is known about the economic burden of treatment.
Purpose—To examine trends in the treated prevalence and treatment costs of nonmelanoma and 
melanoma skin cancers.
Methods—This study used data on adults from the 2002–2011 Medical Expenditure Panel 
Survey full-year consolidated files and information from corresponding medical conditions and 
medical event files to estimate the treated prevalence and treatment cost of nonmelanoma skin 
cancer, melanoma skin cancer, and all other cancer sites. Analyses were conducted in January 
2014.
Results—The average annual number of adults treated for skin cancer increased from 3.4 million 
in 2002–2006 to 4.9 million in 2007–2011 (p<0.001). During this period, the average annual total 
cost for skin cancer increased from $3.6 billion to $8.1 billion (p=0.001), representing an increase 
of 126.2%, while the average annual total cost for all other cancers increased by 25.1%. During 
2007–2011, nearly 5 million adults were treated for skin cancer annually, with average treatment 
costs of $8.1 billion each year.
Conclusions—These findings demonstrate that the health and economic burden of skin cancer 
treatment is substantial and increasing. Such findings highlight the importance of skin cancer 
prevention efforts, which may result in future savings to the healthcare system.
Introduction
Skin cancer, the most commonly diagnosed cancer in the U.S., is increasingly a major public 
health problem. An estimated 3.5 million cases of nonmelanoma skin cancer (NMSC) were 
treated in 2006,1 and more than 60,000 melanomas were diagnosed in 2010.2 The incidence 
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of NMSC and melanoma is increasing,3,4 although little is known about the economic 
burden of treatment. The purpose of this study is to examine trends in the number of adults 
treated for NMSC and melanoma, as well as the associated annual costs of treatment.
Methods
Data on adults from the 2002–2011 Medical Expenditure Panel Survey (MEPS) full-year 
consolidated files were used, as well as information from corresponding medical conditions 
and medical event files. The MEPS combines household-reported data on use and costs, and 
provider-reported data on costs, to provide nationally representative estimates among the 
U.S. civilian noninstitutionalized population. Because data used in these analyses cannot be 
used to personally identify individuals, this study was exempt from IRB review. The 
Clinical Classification Software (CCS) category was used to classify types of cancer as 
nonepithelial cancer of the skin (code 23), melanomas of the skin (code 22), or other cancers 
(codes 11–21 and 24–25).5 Owing to the relatively small number of people reported in 
MEPS as receiving treatment for melanoma (unweighted average of about 150 annually) and 
the skewed distribution of healthcare expenditures, annual estimates among population 
subgroups (e.g., age/gender categories) in general were subject to less statistical precision. 
To allow for a comparison over time and improve the statistical precision of the estimates, 
two 5-year periods of data were created (2002–2006 and 2007–2011). SAS, version 9.2, 
complex survey analysis procedures were used to produce average annual national estimates 
that properly accounted for the MEPS sample design and survey nonresponse. Reported p-
values in the tables are based on simple t-tests of differences between estimates for the two 
time periods.
Individuals were classified as being treated for NMSC, melanoma, or other cancers if they 
had any ambulatory visits (office-based and hospital outpatient), inpatient stays, home health 
visits, or prescribed medication purchases associated with the corresponding CCS code. 
Costs were defined as expenditures from all sources for healthcare services reported in the 
survey, including out of pocket, private insurance, Medicare, Medicaid, and other 
miscellaneous sources. Costs by source of payment and type of service are not reported for 
melanoma because of small sample sizes. All costs were adjusted to 2011 U.S. dollars using 
the Personal Health Care Expenditure Price Index.6 Analyses were conducted in January 
2014.
Results
The average annual number of adults treated for any skin cancer (NMSC or melanoma) 
increased from 3.4 to 4.9 million between 2002–2006 and 2007–2011 (p<0.001), while the 
average number treated for all other cancers increased from 7.8 to 10.3 million (p<0.001, 
Table 1). Subgroup analyses indicated increases among adults aged 65 years and older for 
NMSC (p<0.001) and melanoma (p<0.001), and women aged 18–64 years for melanoma 
(p=0.006).
Between 2002–2006 and 2007–2011, the average annual total cost for skin cancer increased 
by 126.2%, from $3.6 billion to $8.1 billion (p=0.001), while the average annual total cost 
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for all other cancers increased by 25.1%, from $63.7 billion to $79.7 billion (p=0.005, Table 
2). Average annual total treatment costs during 2007–2011 were $4.8 billion for NMSC and 
$3.3 billion for melanoma. During 2007–2011, nearly three quarters of annual NMSC costs 
were attributable to office-based visits compared to one third among all other cancer sites 
(excluding skin cancers). During the same period, private health insurance paid for 43.4% of 
all skin cancer treatment costs while Medicare paid for 41.1%. Among all other cancer sites 
(excluding skin cancer), private health insurance paid for 45.2% of treatment costs, while 
Medicare paid for 36.1%.
Discussion
The number of adults treated for skin cancer increased between 2002–2006 and 2007–2011 
to nearly 5 million adults annually. Average annual total treatment costs for skin cancer also 
increased substantially between these periods to $8.1 billion annually. Increased skin cancer 
treatment costs resulted from an increase in the number of people treated for skin cancer and 
an increase in per person treatment costs. Annual spending increased more rapidly for skin 
cancers than for other cancers, suggesting that the economic burden of skin cancer is a 
particular cause for concern. These findings underscore the importance of prevention and 
early detection of skin cancer.
Although this study demonstrates the substantial costs of skin cancer treatment, it also 
highlights the potential for savings through prevention efforts. Primary prevention efforts 
have been shown to reduce skin cancer incidence, mortality, and healthcare expenditures.7–9 
For example, the Sunwise Program, a health and environmental education program that 
teaches children and their caregivers how to protect themselves from overexposure to the 
sun, could avert nearly 11,000 skin cancer cases, while saving $2–$4 in medical care costs 
and lost productivity for each dollar invested in the program.7 Similarly, in Australia, the 
SunSmart public education program promoting sun protection and skin cancer prevention 
messages through structural, environmental, and legislative initiatives was estimated to save 
22,000 life years, while saving approximately $2 for every dollar invested.8 Reducing indoor 
tanning, which is associated with an increased risk of NMSC and melanoma,10,11 is also an 
important strategy for decreasing the burden of skin cancer.9 In Australia, it was estimated 
that stricter indoor tanning regulations, including age restrictions among minors aged ≤18 
years, could prevent approximately 24 melanoma cases, 226 squamous cell carcinoma cases, 
and save $256,000 in medical costs per 100,000 persons.9 According to the U.S. Preventive 
Services Task Force,12 there is currently insufficient evidence to recommend for or against 
regular skin cancer screening, including self-examination for early detection of skin cancer 
in the adult general population. However, screening among individuals at increased risk for 
melanoma may be cost-effective. For example, one-time screening among high-risk 
individuals in the U.S. was associated with a small increase in life expectancy and was 
reasonably cost-effective.13
Limitations of this study include its reliance on self- or household-reported survey data, 
which are subject to measurement errors. In addition, because institutionalized adults and 
adults in the military are not sampled in the MEPS, the results only apply to the 
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noninstitutionalized civilian adult population, which may result in an underestimation of the 
treated prevalence and treatment costs of skin cancer among adults.
In summary, this study demonstrates that the health and economic burden of skin cancer 
treatment is substantial and increasing. These findings highlight the importance of skin 
cancer prevention and early detection efforts. Such efforts are needed to reduce the 
increasing burden of skin cancer in the U.S.
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